MedAvail Holdings, Inc. reaffirmed revenue guidance for the full year 2023. The company expects total revenue for the pharmacy technology business to be approximately $3 million, which would represent greater than 100% growth over 2022 pharmacy technology revenue of $1.4 million. In addition, the company expects to place 25 net new dispensing MedCenters in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | -.--% | -.--% | -100.00% |
05-06 | Motion for Asset Sale Filed by MedAvail Holdings, Inc. | CI |
05-03 | Notice of Successful Bidder Filed by MedAvail Holdings, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
-100.00% | 322 | |
+16.68% | 87.2B | |
+21.80% | 72.13B | |
+18.00% | 36.82B | |
+25.04% | 34.67B | |
+12.66% | 28.34B | |
+4.41% | 27.06B | |
+6.88% | 26.98B | |
+20.37% | 26.3B | |
+20.64% | 25.5B |
- Stock Market
- Equities
- MYOS Stock
- News MedAvail Holdings, Inc.
- MedAvail Holdings, Inc. Reaffirms Revenue Guidance for the Full Year 2023